| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001861662 |
| P356 | DOI | 10.2165/00002018-200427020-00002 |
| P698 | PubMed publication ID | 14717621 |
| P50 | author | Piero Marchetti | Q37382607 |
| Fabio Vistoli | Q55345435 | ||
| Romano Danesi | Q67479522 | ||
| P2093 | author name string | Mario Del Tacca | |
| Ugo Boggi | |||
| Franco Mosca | |||
| Marco Del Chiaro | |||
| Stefano Signori | |||
| P2860 | cites work | Basiliximab | Q33585369 |
| Advances in interleukin 2 receptor targeted treatment | Q34071328 | ||
| Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy | Q34094929 | ||
| Signaling domains of the interleukin 2 receptor | Q34252892 | ||
| Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. | Q34331859 | ||
| Tailoring immunosuppressive therapy for renal transplant recipients | Q34459657 | ||
| Reducing adverse effects of immunosuppressive agents in kidney transplant recipients | Q34547749 | ||
| Options for induction immunosuppression in liver transplant recipients | Q34621443 | ||
| Clinical development of Orthoclone OKT3. | Q39594146 | ||
| Uremia as a State of Immune Deficiency | Q39767280 | ||
| Immune system dysregulation in uremia. | Q40674928 | ||
| Elimination of the immunogenicity of therapeutic antibodies | Q40964758 | ||
| Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts | Q42670216 | ||
| Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. | Q42679476 | ||
| Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients | Q43551295 | ||
| An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation | Q43592410 | ||
| Economic analysis of basiliximab in renal transplantation | Q43660951 | ||
| Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients | Q43687549 | ||
| Basiliximab induction improves the outcome of renal transplants in children and adolescents. | Q43712111 | ||
| A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients | Q43768141 | ||
| Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients | Q43828434 | ||
| CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab in cadaveric kidney transplantation | Q43828442 | ||
| Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation | Q43828444 | ||
| Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab | Q43828451 | ||
| Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study | Q43828689 | ||
| Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection | Q43843796 | ||
| Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. | Q43855939 | ||
| Single centre experience with basiliximab in paediatric renal transplantation | Q43867643 | ||
| Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction | Q43966601 | ||
| Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation | Q44053836 | ||
| Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients | Q44101569 | ||
| Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients | Q44104890 | ||
| Report on management of renal failure in children in Europe, XXII, 1991 | Q44624091 | ||
| Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation | Q47784519 | ||
| Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group | Q47887130 | ||
| A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. | Q52029967 | ||
| Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. | Q52136678 | ||
| Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction | Q57371171 | ||
| CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS | Q61651679 | ||
| Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients | Q61651688 | ||
| Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients | Q67249842 | ||
| A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants | Q69865410 | ||
| A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation | Q70999050 | ||
| The humoral immune response towards HLA class II determinants in renal transplantation | Q71769742 | ||
| Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group | Q72995990 | ||
| Anaphylactic shock after retreatment with basiliximab | Q73013464 | ||
| A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation | Q73117695 | ||
| Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients | Q73176253 | ||
| Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group | Q73207716 | ||
| Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection | Q73207762 | ||
| Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events | Q73370304 | ||
| Delayed graft function incidence as predictive variable of survival of kidney grafts retrieved from elderly donors | Q73506841 | ||
| A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation | Q73774364 | ||
| Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group | Q74038855 | ||
| Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus | Q74493986 | ||
| Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group | Q74602309 | ||
| Screening for basiliximab exposure-response relationships in renal allotransplantation | Q74613772 | ||
| Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine | Q77916232 | ||
| Kidney transplantation between seven pairs of identical twins | Q78313975 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 91-106 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | A benefit-risk assessment of basiliximab in renal transplantation | |
| P478 | volume | 27 |
| Q42684792 | Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease |
| Q35910576 | Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus |
| Q26830569 | Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets |
| Q36649380 | Critical care perspective on immunotherapy in lung transplantation |
| Q36150553 | Efficacy and safety of basiliximab in kidney transplantation. |
| Q36441441 | Post-transplant lymphoproliferative disease: association with induction therapy? |
| Q46109510 | Remission of refractory minimal change nephrotic syndrome after basiliximab therapy |
| Q38023207 | Targeted immunotherapy trials for idiopathic inflammatory myopathies |
| Q43078141 | The role of basiliximab in the evolving renal transplantation immunosuppression protocol |
Search more.